Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 19/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14646806 | 0.79 | CCNT1 (0.58) | CCNT1CDK9BTK | |
| SCHEMBL14500649 | 0.74 | CCNT1 (0.67) | CCNT1CDK9BTK | |
| SCHEMBL14646746 | 0.73 | BTK (0.69) | BTK | |
| SCHEMBL14645726 | 0.71 | BTK (0.72) | BTK | |
| SCHEMBL16049023 | 0.71 | BTK (0.63) | CCNT1CDK9BTK | |
| SCHEMBL18992876 | 0.70 | CCNT1 (0.30) | CCNT1CDK9 | |
| SCHEMBL14645723 | 0.70 | BTK (0.70) | BTK | |
| SCHEMBL14646842 | 0.70 | BTK (0.68) | BTK | |
| SCHEMBL16049399 | 0.69 | BTK (0.66) | CCNT1CDK9BTK | |
| SCHEMBL14646741 | 0.69 | BTK (0.72) | CCNT1CDK9BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390361-A1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | Incyte Corporation (US) | 2018-10-24 | — | — | EP | claimed |
| US-20180273519-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-09-27 | — | — | US | claimed |
| WO-2017106634-A1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | INCYTE CORPORATION (US) | 2017-06-22 | — | — | WO | claimed |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-06-22 | — | — | US | claimed |
| EP-3390361-A1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | Incyte Corporation (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180273519-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-09-27 | — | — | US | disclosed |
| WO-2017106634-A1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | INCYTE CORPORATION (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273519-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CCNT1 1163/4885CDK9 1088/4885BTK 1049/4885 |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CCNT1 1163/4885CDK9 1088/4885BTK 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.